Although the clinical value of hENT1 in the transport of gemcitabine in many cancers has been demonstrated by immunohistochemical staining elsewhere [9–11, 18, 19, 21, 22], there is no standardized method for discrimination among clinical outcomes. Here, SLC29A1 is linked to cancer.